Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShort-Term Debt issuances
Ratios

Astrazeneca (AZNCF) Other Gross PP&E Adjustments (2019 - 2025)

Historic Other Gross PP&E Adjustments for Astrazeneca (AZNCF) over the last 14 years, with Q4 2025 value amounting to -$1.7 billion.

  • Astrazeneca's Other Gross PP&E Adjustments fell 2480.29% to -$1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.7 billion, marking a year-over-year decrease of 2480.29%. This contributed to the annual value of -$1.7 billion for FY2025, which is 2480.29% down from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Other Gross PP&E Adjustments is -$1.7 billion, which was down 2480.29% from -$1.7 billion recorded in Q3 2025.
  • Astrazeneca's Other Gross PP&E Adjustments' 5-year high stood at -$660.0 million during Q1 2021, with a 5-year trough of -$1.7 billion in Q4 2025.
  • For the 5-year period, Astrazeneca's Other Gross PP&E Adjustments averaged around -$1.1 billion, with its median value being -$982.5 million (2021).
  • In the last 5 years, Astrazeneca's Other Gross PP&E Adjustments plummeted by 9340.0% in 2021 and then skyrocketed by 770.04% in 2022.
  • Over the past 5 years, Astrazeneca's Other Gross PP&E Adjustments (Quarter) stood at -$988.0 million in 2021, then grew by 4.66% to -$942.0 million in 2022, then dropped by 16.77% to -$1.1 billion in 2023, then decreased by 26.82% to -$1.4 billion in 2024, then decreased by 24.8% to -$1.7 billion in 2025.
  • Its Other Gross PP&E Adjustments was -$1.7 billion in Q4 2025, compared to -$1.7 billion in Q3 2025 and -$1.6 billion in Q2 2025.